| scholarly article | Q13442814 |
| P50 | author | Nicolas Merienne | Q57780749 |
| Emilie Faivre | Q114416290 | ||
| Juliette Le Douce | Q114416306 | ||
| Gilles Bonvento | Q43141211 | ||
| Nicole Déglon | Q47503901 | ||
| P2860 | cites work | Functional recovery in parkinsonian monkeys treated with GDNF | Q24312738 |
| Antiviral restriction factor transgenesis in the domestic cat | Q24567554 | ||
| Towards a transgenic model of Huntington's disease in a non-human primate | Q24644013 | ||
| Astrocytes: biology and pathology | Q27490746 | ||
| Identification of tissue-specific microRNAs from mouse | Q27860892 | ||
| Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics | Q28141424 | ||
| Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain | Q28270111 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| The mystery and magic of glia: a perspective on their roles in health and disease | Q28300305 | ||
| A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors | Q28510246 | ||
| Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132 | Q28510360 | ||
| Expression of mutant N-terminal huntingtin fragment (htt552-100Q) in astrocytes suppresses the secretion of BDNF. | Q48618710 | ||
| Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats | Q48684249 | ||
| Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. | Q48939757 | ||
| Astrocytes infected with replication-defective adenovirus containing a secreted form of CNTF or NT3 show enhanced support of neuronal populations in vitro | Q48983208 | ||
| Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells | Q50064805 | ||
| Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo | Q50105432 | ||
| Gene therapy and targeted toxins for glioma | Q57006162 | ||
| An evaluation of site-specific immune responses directed against first-generation adenoviral vectors administered by convection-enhanced delivery | Q64379765 | ||
| Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease | Q64383353 | ||
| Microglia and astrocytes in the adult rat brain: comparative immunocytochemical analysis demonstrates the efficacy of lipocortin 1 immunoreactivity | Q73466564 | ||
| GFAP promoter elements required for region-specific and astrocyte-specific expression | Q80607573 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery | Q39442534 | ||
| Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. | Q39721811 | ||
| Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding | Q39756934 | ||
| Stable knockdown of microRNA in vivo by lentiviral vectors | Q39910684 | ||
| Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus | Q40074841 | ||
| Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. | Q40117295 | ||
| Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. | Q40151445 | ||
| Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. | Q40163481 | ||
| Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides | Q40273519 | ||
| Astrocytic expression of transgene in the rat brain mediated by baculovirus vectors containing an astrocyte-specific promoter | Q40275505 | ||
| Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease | Q40326219 | ||
| Retroviral vectors directed to predefined cell types for gene therapy. | Q40449730 | ||
| Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. | Q40478813 | ||
| Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins | Q40583034 | ||
| A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function | Q29547320 | ||
| An anatomically comprehensive atlas of the adult human brain transcriptome | Q29614949 | ||
| Tripartite synapses: glia, the unacknowledged partner | Q29615224 | ||
| Architecture of the human regulatory network derived from ENCODE data | Q29617046 | ||
| Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs | Q29618428 | ||
| Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms | Q30492587 | ||
| Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease | Q31132651 | ||
| Applications of lentiviral vectors for biology and gene therapy of neurological disorders. | Q33392246 | ||
| Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression | Q33551268 | ||
| Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy | Q33700352 | ||
| Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. | Q33713108 | ||
| Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice | Q33796172 | ||
| Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. | Q33819663 | ||
| Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo | Q33844362 | ||
| In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects | Q33980357 | ||
| MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration | Q34101214 | ||
| Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model | Q34105795 | ||
| Characterization of adeno-associated virus genomes isolated from human tissues | Q34142848 | ||
| Specification and Morphogenesis of Astrocytes | Q34148201 | ||
| A regulatory toolbox of MiniPromoters to drive selective expression in the brain | Q34151669 | ||
| Identification of PDGFR as a receptor for AAV-5 transduction | Q34264144 | ||
| Exploiting microRNA regulation for genetic engineering | Q34302499 | ||
| Current status of gene therapy for brain tumors. | Q34318157 | ||
| AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method | Q34330377 | ||
| Regulation of miRNA expression during neural cell specification | Q34412991 | ||
| Selective and rapid uptake of adeno-associated virus type 2 in brain | Q34471578 | ||
| Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. | Q34486856 | ||
| Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra | Q34572037 | ||
| Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 | ||
| Gene delivery by lentivirus vectors | Q34688367 | ||
| Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. | Q34787342 | ||
| Engineered lentiviral vector targeting astrocytes in vivo | Q34862612 | ||
| Gene expression profiling to define host response to baculoviral transduction in the brain | Q34983484 | ||
| Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy | Q35011497 | ||
| The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice | Q35015807 | ||
| Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease | Q40599126 | ||
| Encapsulation of packaging cell line results in successful retroviral-mediated transfer of a suicide gene in vivo in an experimental model of glioblastoma | Q40652788 | ||
| Interaction of adenoviral proteins with pRB and p53. | Q40831467 | ||
| Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. | Q40874496 | ||
| Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease | Q40904090 | ||
| Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease | Q40906891 | ||
| Adeno-associated virus expression systems for gene transfer | Q40994121 | ||
| Gene- and viral-based therapies for brain tumors | Q42135456 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. | Q42352469 | ||
| Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union | Q42516930 | ||
| A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. | Q42639115 | ||
| Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis | Q42643268 | ||
| Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes | Q42739394 | ||
| In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats | Q42813300 | ||
| The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats | Q42835030 | ||
| Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. | Q43109280 | ||
| A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons | Q43244050 | ||
| Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. | Q43764350 | ||
| Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration | Q43876009 | ||
| Lentiviral gene transfer to the nonhuman primate brain | Q44028201 | ||
| Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector | Q44776741 | ||
| Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system | Q45007196 | ||
| The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain | Q45280305 | ||
| Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. | Q45296827 | ||
| Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype | Q45303314 | ||
| Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain | Q45420843 | ||
| Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. | Q45451131 | ||
| Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia | Q45556174 | ||
| Adeno-associated virus vector-mediated transduction in the cat brain | Q45711198 | ||
| A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 | ||
| A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma | Q45752309 | ||
| A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group | Q45862712 | ||
| Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain | Q45864411 | ||
| Gap junctions in human glioblastomas: implications for suicide gene therapy | Q45872003 | ||
| Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state | Q45872960 | ||
| An adenovirus vector for gene transfer into neurons and glia in the brain | Q45874317 | ||
| The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS. | Q45874689 | ||
| Towards gene therapy for Parkinson's disease | Q45876470 | ||
| Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy | Q45877447 | ||
| A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease | Q45883058 | ||
| Binding of adenovirus to its receptors in mouse astrocytes induces c-fos proto-oncogene and apoptosis | Q45887257 | ||
| Impaired glutamate transport in a mouse model of tau pathology in astrocytes. | Q46890621 | ||
| GFAP promoter directs astrocyte-specific expression in transgenic mice | Q48163933 | ||
| Adenovirus-mediated transgene expression in nonhuman primate brain | Q48201318 | ||
| Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport | Q48435478 | ||
| GFAP-expressing cells in the postnatal subventricular zone display a unique glial phenotype intermediate between radial glia and astrocytes | Q48456009 | ||
| Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells | Q48587406 | ||
| Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6 | Q35024289 | ||
| Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates | Q35086714 | ||
| Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. | Q35111738 | ||
| Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. | Q35118919 | ||
| Viral vectors for gene delivery to the nervous system | Q35120134 | ||
| Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes | Q35139648 | ||
| Cell-type-based analysis of microRNA profiles in the mouse brain. | Q35725749 | ||
| Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis | Q35809290 | ||
| Astrocytes and disease: a neurodevelopmental perspective | Q35945056 | ||
| Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo | Q35948485 | ||
| Viral vectors as tools to model and treat neurodegenerative disorders | Q36009671 | ||
| HSV trafficking and development of gene therapy vectors with applications in the nervous system | Q36134871 | ||
| Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid | Q36155479 | ||
| Reprogramming axonal behavior by axon-specific viral transduction | Q36185929 | ||
| Functional analysis of transcription factor binding sites in human promoters | Q36378033 | ||
| General principals of miRNA biogenesis and regulation in the brain. | Q36465866 | ||
| MicroRNA expression in the adult mouse central nervous system | Q36470289 | ||
| Identification of a heparin-binding motif on adeno-associated virus type 2 capsids | Q36474230 | ||
| The neuronal microRNA system | Q36657801 | ||
| Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. | Q36793180 | ||
| Timing is everything: making neurons versus glia in the developing cortex | Q36811626 | ||
| Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia | Q36851040 | ||
| Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector | Q37251114 | ||
| Integration-deficient lentiviral vectors: a slow coming of age. | Q37506025 | ||
| Oncolytic viral therapy of malignant glioma | Q37533665 | ||
| Chromosomal tethering and proviral integration | Q37580331 | ||
| Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond | Q37642283 | ||
| Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus | Q37660700 | ||
| In vivo targeting of subventricular zone astrocytes. | Q37742223 | ||
| Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil | Q37756317 | ||
| Astrocyte heterogeneity: an underappreciated topic in neurobiology | Q37775248 | ||
| HSV Recombinant Vectors for Gene Therapy | Q37787777 | ||
| Gene therapy and virotherapy: novel therapeutic approaches for brain tumors | Q37804933 | ||
| Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases | Q37959706 | ||
| Genetic approaches to study glial cells in the rodent brain. | Q37967602 | ||
| Adenovirus receptors: implications for targeting of viral vectors | Q38012560 | ||
| P921 | main subject | astrocyte | Q502961 |
| P304 | page(s) | 106 | |
| P577 | publication date | 2013-07-05 | |
| P1433 | published in | Frontiers in Cellular Neuroscience | Q2131509 |
| P1476 | title | Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors | |
| P478 | volume | 7 |
| Q36339790 | A neuronal MCT2 knockdown in the rat somatosensory cortex reduces both the NMR lactate signal and the BOLD response during whisker stimulation |
| Q36099101 | A new minimally-invasive method for microinjection into the mouse spinal dorsal horn |
| Q47160278 | AAV-Mediated Astrocyte-Specific Gene Expression under Human ALDH1L1 Promoter in Mouse Thalamus |
| Q92955124 | Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following injury |
| Q38839272 | Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease |
| Q37177095 | Astrocytic Acid-Sensing Ion Channel 1a Contributes to the Development of Chronic Epileptogenesis |
| Q47137633 | Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection |
| Q41643528 | Gene transfer engineering for astrocyte-specific silencing in the CNS. |
| Q38255735 | Imaging and monitoring astrocytes in health and disease |
| Q89637724 | Improved tools to study astrocytes |
| Q97681331 | In vivo locus-specific editing of the neuroepigenome |
| Q27026844 | Large-scale recording of astrocyte activity |
| Q38903989 | MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain |
| Q97424187 | Maximizing lentiviral vector gene transfer in the CNS |
| Q89567009 | Neuronal HIF-1α in the nucleus tractus solitarius contributes to ventilatory acclimatization to hypoxia |
| Q39287516 | Neuroprotection Induced by Transplanted CDK5 Knockdown Astrocytes in Global Cerebral Ischemic Rats. |
| Q28818470 | Pigmy MicroRNA: surveillance cops in Therapies kingdom |
| Q55280382 | Reactive Astrocytes as Drug Target in Alzheimer's Disease. |
| Q37412106 | Recent molecular approaches to understanding astrocyte function in vivo |
| Q40434024 | Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes In vitro and In vivo. |
| Q37051728 | Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease |
Search more.